Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Neurocrine (NBIX) and Tarsus Pharmaceuticals (TARS)
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $67
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Tarsus Pharmaceuticals Analyst Ratings
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $67
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $61
Analysts' Top Healthcare Picks: Chromadex (CDXC), Tarsus Pharmaceuticals (TARS)
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
HC Wainwright & Co. : Tarsus Pharmaceuticals (TARS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $57.00 to $61.00.
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $61
Barclays: Maintaining the Tarsus Pharmaceuticals (TARS.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $50.00 to $60.00.
Tarsus Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
Oppenheimer: The Tarsus Pharmaceuticals (TARS.US) rating was maintained, and the target price was adjusted from better than the market to the superior market rating, and the target price was adjusted from $59.00 to $61.00.